Previous studies have linked elevated IFITM3 expression to tumor progression in glioblastoma, gastric, and hepatocellular carcinomas, where it regulates key pathways, such as cell proliferation, angiogenesis, and epithelial-mesenchymal transition (EMT) [40–42]. Here, IFITM3 is linked to neoplasm.